Genmab A/S (NASDAQ:GMAB) Stock Price Expected to Rise, HC Wainwright Analyst Says

Genmab A/S (NASDAQ:GMAB) had its price target upped by HC Wainwright from $40.00 to $50.00 in a report released on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 32.28% from the company’s previous close.

A number of other research analysts also recently commented on GMAB. Weiss Ratings raised shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, September 1st. Guggenheim increased their price objective on shares of Genmab A/S from $45.00 to $54.00 and gave the company a “buy” rating in a research note on Monday. TD Cowen raised shares of Genmab A/S from a “hold” rating to a “buy” rating and lifted their price objective for the company from $32.00 to $43.00 in a report on Wednesday, July 22nd. Finally, New Street Research set a $43.00 price objective on shares of Genmab A/S in a research note on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Genmab A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.94.

Genmab A/S Price Performance

GMAB opened at $37.80 on Wednesday. Genmab A/S has a 12-month low of $23.62 and a 12-month high of $40.17. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. The business’s fifty day simple moving average is $33.13 and its 200-day simple moving average is $29.15. The company has a market capitalization of $23.59 billion, a price-to-earnings ratio of 29.76, a PEG ratio of 2.09 and a beta of 0.81.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.17. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. On average, equities research analysts anticipate that Genmab A/S will post 1.21 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Hedge funds have recently modified their holdings of the company. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Genmab A/S by 36.6% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after buying an additional 1,334,919 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Genmab A/S by 26.4% during the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock worth $118,442,000 after acquiring an additional 921,700 shares in the last quarter. First Trust Advisors LP lifted its position in Genmab A/S by 84.3% during the first quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock valued at $66,038,000 after acquiring an additional 1,126,069 shares during the last quarter. Quantinno Capital Management LP lifted its position in Genmab A/S by 14.4% during the first quarter. Quantinno Capital Management LP now owns 282,498 shares of the company’s stock valued at $7,579,000 after acquiring an additional 35,588 shares during the last quarter. Finally, Royal Bank of Canada boosted its stake in Genmab A/S by 1.8% in the first quarter. Royal Bank of Canada now owns 150,135 shares of the company’s stock valued at $4,029,000 after acquiring an additional 2,637 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates.